BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27488874)

  • 21. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
    Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
    Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
    Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; Del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; du Bois A
    Gynecol Oncol; 2016 Mar; 140(3):443-9. PubMed ID: 26740259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).
    Scalici JM; Arapovic S; Saks EJ; Atkins KA; Petroni G; Duska LR; Slack-Davis JK
    Cancer; 2017 May; 123(6):977-984. PubMed ID: 28263384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer.
    Mahdi H; Gockley A; Esselen K; Marquard J; Nutter B; Yang B; Hinchcliff E; Horowitz N; Rose PG
    Gynecol Oncol; 2015 Dec; 139(3):407-12. PubMed ID: 26210778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
    Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
    Spearman AD; Sweet K; Zhou XP; McLennan J; Couch FJ; Toland AE
    J Clin Oncol; 2008 Nov; 26(33):5393-400. PubMed ID: 18824701
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Liontos M; Zografos E; Zoumpourlis P; Andrikopoulou A; Svarna A; Fiste O; Kunadis E; Papatheodoridi AM; Kaparelou M; Koutsoukos K; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
    Curr Oncol; 2021 Nov; 28(6):4446-4456. PubMed ID: 34898566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study.
    Muñoz-Repeto I; García MJ; Kamieniak M; Ramón Y Cajal T; Domingo S; Cazorla A; García Donas J; Hernando Polo S; García Sagredo JM; Hernández E; Lacambra C; Saez R; Robles L; Borrego S; Prat J; Palacios J; Benítez J
    Histol Histopathol; 2013 Jan; 28(1):133-44. PubMed ID: 23233066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
    Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
    Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
    Belanger MH; Dolman L; Arcand SL; Shen Z; Chong G; Mes-Masson AM; Provencher D; Tonin PN
    J Ovarian Res; 2015 Mar; 8():1. PubMed ID: 25884701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No association between BRCA1 immunohistochemical expression and tumor grade, stage or overall survival in platinum-treated epithelial ovarian cancer patients.
    Shawky Ael-A; El-Hafez AA; El-Tantawy D; Hamdy R
    Asian Pac J Cancer Prev; 2014; 15(10):4275-9. PubMed ID: 24935384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved survival in women with BRCA-associated ovarian carcinoma.
    Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
    Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.
    Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB
    Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.
    Xu K; Yang S; Zhao Y
    Oncotarget; 2017 Jan; 8(1):285-302. PubMed ID: 27690218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
    Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
    J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
    Sabatier R; Lavit E; Moretta J; Lambaudie E; Noguchi T; Eisinger F; Cherau E; Provansal M; Livon D; Rabayrol L; Popovici C; Charaffe-Jauffret E; Sobol H; Viens P
    Fam Cancer; 2016 Oct; 15(4):497-506. PubMed ID: 26833043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups.
    Safra T; Lai WC; Borgato L; Nicoletto MO; Berman T; Reich E; Alvear M; Haviv I; Muggia FM
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii63-viii68. PubMed ID: 24131973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.
    Liu J; Cristea MC; Frankel P; Neuhausen SL; Steele L; Engelstaedter V; Matulonis U; Sand S; Tung N; Garber JE; Weitzel JN
    Cancer Genet; 2012; 205(1-2):34-41. PubMed ID: 22429596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved survival in BRCA2 carriers with ovarian cancer.
    Pal T; Permuth-Wey J; Kapoor R; Cantor A; Sutphen R
    Fam Cancer; 2007; 6(1):113-9. PubMed ID: 17160431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.